Last reviewed 2026-04-23 · How we verify

Orca-T

Orca-T is a monoclonal antibody that targets the PD-1 receptor.

Orca-T is a monoclonal antibody that targets the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.

At a glance

Mechanism of action

By binding to PD-1, Orca-T prevents the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively. This mechanism is thought to be responsible for the drug's anti-tumor activity.

Approved indications

• Metastatic non-small cell lung cancer, PD-L1 positive
• Metastatic melanoma

Common side effects

• Fatigue
• Diarrhea
• Nausea
• Rash
• Hypertension

Key clinical trials

• Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (PHASE3)
• Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome (PHASE2)
• Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT (PHASE1)
• Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
• Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome (PHASE1)
• Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL (PHASE1)
• Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.